Contact
searchSearch
HMP Global

Psoriatic Arthritis Topic Center

Featured Article

News
Managing Treatment Burden in PsA and RA: Patients' Views on Methotrexate and TNFi Use
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
Bimekizumab is Safe and Effective in Treating Patients With Psoriatic Arthritis Native to Biologic Treatment, Study Finds
11/15/2023
Lisa Kuhns, PhD, MD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
Early Detection Tool for Psoriatic Arthritis in Psoriasis Patients
10/24/2023
Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care
News
Persistence, Switching in Patients With PsA Similar With Ixekizumab and Secukinumab
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
New and Previous Chronic Inflammatory Disease Diagnoses Increases Treatment Costs
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
Cardiometabolic, Mental Health Disorders Common in Patients With PsA
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care
News
Sleep Problems Common Among Patients With Psoriatic Arthritis
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
Synovio-Enthesitis on Ultrasound May Detect Subclinical PsA
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
IL-23 Inhibitors Outperform Placebo for Treatment of Psoriatic Arthritis, Meta-Analysis Shows
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care
News
IL-17A Inhibition With Treatment Improves Symptoms of Psoriatic Arthritis
10/27/2022
Edan Stanley
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler...
10/27/2022
First Report Managed Care

Newsfeed

News
Managing Treatment Burden in PsA and RA: Patients' Views on Methotrexate and TNFi Use
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
Bimekizumab is Safe and Effective in Treating Patients With Psoriatic Arthritis Native to Biologic Treatment, Study Finds
11/15/2023
Lisa Kuhns, PhD, MD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
Early Detection Tool for Psoriatic Arthritis in Psoriasis Patients
10/24/2023
Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care
News
Persistence, Switching in Patients With PsA Similar With Ixekizumab and Secukinumab
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
New and Previous Chronic Inflammatory Disease Diagnoses Increases Treatment Costs
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
Cardiometabolic, Mental Health Disorders Common in Patients With PsA
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care
News
Sleep Problems Common Among Patients With Psoriatic Arthritis
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
Synovio-Enthesitis on Ultrasound May Detect Subclinical PsA
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
IL-23 Inhibitors Outperform Placebo for Treatment of Psoriatic Arthritis, Meta-Analysis Shows
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care
News
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
04/20/2026
Grace Taylor, MS, MA
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study,...
04/20/2026
First Report Managed Care
News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Real-World Data Show Semaglutide’s Impact on Health Care Utilization and Medical Costs for Patients With OW/OB
04/17/2026
Rebecca Amrick
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a...
04/17/2026
First Report Managed Care
News
Improving RVU Compensation Models to be More Equitable for Transplant Nephrologists
04/16/2026
Rebecca Amrick
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines...
04/16/2026
First Report Managed Care
News
Mail-Based FIT Program Increases CRC Screening in a Value-Based Care System
04/13/2026
Rebecca Amrick
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health...
04/13/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Delays in Early-Stage NSCLC Surgery Linked to Systemic and Equity Gaps in Patients
04/13/2026
Rebecca Amrick
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
Behind the Bill
CMS Proposes FY 2027 Skilled Nursing Facility Payment and Quality Updates
04/10/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare &...
04/10/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use